Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Atherosclerosis (or arteriosclerotic vascular disease) may occur with symptoms including chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

The Atherosclerosis pipeline drugs market research report outlays comprehensive information on the Atherosclerosis targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Atherosclerosis targeted therapeutics development with respective active and dormant or discontinued projects.

Atherosclerosis Pipeline Drugs Market Segmentation by Targets

Some of the primary targets in the Atherosclerosis pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9, Apolipoprotein A, Cannabinoid Receptor 1, Transforming Growth Factor Beta ), Angiopoietin Related Protein 3, Apolipoprotein A I, ATP Binding Cassette Sub Family A Member 1, Cholesteryl Ester Transfer Protein. Proprotein Convertase Subtilisin/Kexin Type 9 accounted for the largest target in the Atherosclerosis pipeline drugs market.

Atherosclerosis Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the Atherosclerosis pipeline drugs market, download a free report sample

Atherosclerosis Pipeline Drugs Market Segmentation by Mechanisms of Action

The primary mechanisms of action in the Atherosclerosis pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Apolipoprotein A Inhibitor, Cannabinoid Receptor 1 Antagonist, Angiopoietin Related Protein 3 Inhibitor, Apolipoprotein A I Activator, Cholesteryl Ester Transfer Protein Inhibitor, Interleukin 6 Inhibitor, Transforming Growth Factor Beta Inhibitor, and Adenosine A2 Receptor Agonist. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor has the maximum number of products in the Atherosclerosis pipeline drugs market.

Atherosclerosis Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the Atherosclerosis pipeline drugs market, download a free report sample

Atherosclerosis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Atherosclerosis pipeline drugs market are oral, subcutaneous, intravenous, parenteral, topical, intraarticular, intrathecal, and ophthalmic. Oral has the majority number of products in the Atherosclerosis pipeline drugs market.

Atherosclerosis Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the Atherosclerosis pipeline drugs market, download a free report sample

Atherosclerosis Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types in the Atherosclerosis pipeline drugs market are Small Molecule, Monoclonal Antibody, Cell Therapy, Recombinant Protein, Antisense Oligonucleotide, Synthetic Peptide, and Peptide among others.

Atherosclerosis Pipeline Drugs Market Analysis, by Molecule Type

To know more about the molecule type in the Atherosclerosis pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Atherosclerosis pipeline drugs market are Vasocure Therapeutics, AstraZeneca Plc, Novartis AG, CRISPR Therapeutics AG, Jenrin Discovery Inc, Novo Nordisk AS, Amgen Inc among others. Vasocure Therapeutics accounted for the largest Atherosclerosis pipeline drugs market share in 2021.

Atherosclerosis Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the Atherosclerosis pipeline drugs market, download a free report sample

Atherosclerosis Pipeline Drugs Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.